|
Delayed
Japan Exchange
01:30:00 2026-11-17 EST
|
5-day change | 1st Jan Change | ||
| 6,931.00 JPY | -0.09% |
|
+3.87% | +43.35% |
| 11-16 | Keros Therapeutics Approves $5 Million Buyback After Drug Milestone Payment | DJ |
| 11-16 | Keros Therapeutics Authorizes $5 Million Share Repurchase Program | MT |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 11,071,918 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 23.74% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 15,025,490 | 14,788,249 | 14,447,461 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 192.87% | -1.58% | -2.3% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 49.6x | 34x | 27.7x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.49x | 1.49x | 1.48x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 3.4x | 0.7x | 1.2x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 2.35x | 2.29x | 2.23x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 3.18x | 3.06x | 2.9x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 12.3x | 11.1x | 10.4x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 32x | 23.5x | 19.8x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 26.9x | 20.1x | 18.6x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 3.72% | 4.97% | 5.38% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 214.9 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 2.95% | 3.01% | 3.1% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 139.7 | 204.1 | 249.9 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 146% | 102% | 86% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,721,475 | 4,836,711 | 4,973,426 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,216,836 | 1,328,786 | 1,392,731 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 469,822 | 629,207 | 728,116 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 211,509 | 343,306 | 411,949 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,953,572 | 3,716,331 | 3,375,543 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 6,931.00 | 6,931.00 | 6,931.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,597,449 | - | - |
| Announcement Date | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 49.77x | 3.19x | 12.6x | 2.95% | 69.43B | ||
| 41.9x | 14.18x | 30.07x | 0.48% | 1,275B | ||
| 41.35x | 6.94x | 19.51x | 1.89% | 680B | ||
| 37.55x | 8.61x | 17.78x | 2.34% | 521B | ||
| 22x | 5.33x | 13.34x | 2.45% | 389B | ||
| 102.54x | 5.86x | 24.97x | 2.35% | 356B | ||
| 24.41x | 5.87x | 14.28x | 2.7% | 305B | ||
| 24.28x | 4.86x | 13.64x | 1.8% | 287B | ||
| 23.87x | 7.33x | 13.47x | 2.18% | 250B | ||
| -39.41x | 7.29x | 45.94x | 1.97% | 208B | ||
| Average | 32.83x | 6.95x | 20.56x | 2.11% | 434B | |
| Weighted average by Cap. | 37.28x | 8.80x | 22.35x | 1.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
















